Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bacillus Subtilis
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Bacillus Subtilis
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bacillus Subtilis Spore Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : DreamTec Cytokine Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
Details : Bacillus Subtilis Spore Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Bacillus Subtilis Spore Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : DreamTec Cytokine Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bacillus Subtilis
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 27, 2021
Lead Product(s) : Bacillus Subtilis
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable